CRO

GVK inks deal with FDA for 'drug repositioning'

India's GVK Biosciences has added another big name to its list of clients, licensing its proprietary databases to help the FDA identify alternative indications for drugs already on the market, seeing if they can treat neglected and orphan diseases. GVK's databases contain more than 6.5 million compounds, and over the past year, the company has linked up with Onconova, Endo Pharmaceuticals ($ENDP) and the University of Dundee. More